| abstract |
The invention relates to the use of CD89 activating molecules, in particular molecules comprising Fc alpha, and more particularly, IgA, to induce apoptosis in neutrophils. Anti-CD89 antibodies can be used alternatively. The activation of CD89 is beneficial in the treatment of various disorders associated with the increase in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis. |